Prognostic significance of CD147 in patients with glioblastoma

Journal of Neuro-Oncology

Volumn 115, Issue 1, 2013, Pages 19-26

  Yang, Min ^c   Yuan, Yang ^a,b   Zhang, Hua ^a   Yan, Ming ^c   Wang, Shumei ^a   Feng, Fuqiang ^a   Ji, Peigang ^a   Li, Yi ^a   Li, Baofu ^a   Gao, Guodong ^a   Zhao, Jipei ^a   Wang, Liang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b No 107 Hospital of PLA   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD147; Glioblastoma; Immunohistochemistry; Prognosis

Indexed keywords

CD147 ANTIGEN; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE MUTATION; GLIOBLASTOMA; HEREDITY; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD147; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84885483996     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1207-2     Document Type: Article

References (40)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507. doi: 10.1056/NEJMra0708126
2. Stupp R, Tonn JC, Brada M, Pentheroudakis G, Group EGW (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190-v193. doi: 10.1093/annonc/mdq187
3. Stupp R, Hegi M, Weller M (2010) Neuro-oncology, a decade of temozolomide and beyond. Expert Rev Anticancer Ther 10(11):1675-1677. doi: 10.1586/era.10.161
4. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712-2718. doi: 10.1200/JCO.2009.26.6650
5. Gupta K, Salunke P (2012) Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 138(12):1971-1981. doi: 10.1007/s00432-012-1323-y
6. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML (2006) Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 24(10):1627-1632. doi: 10.1200/JCO.2005.04.0402
7. Zhao S, Yang G, Mu Y, Han D, Shi C, Chen X, Deng Y, Zhang D, Wang L, Liu Y, Hou X, Wang C, Wu J, Liu H, Wang L, Zhang G, Qi J, Fang X, Shi C, Ai J (2013) MiR-106a is an independent prognostic marker in patients with glioblastoma. Neuro-Oncol. doi: 10.1093/neuonc/not001
8. Rosati A, Poliani PL, Todeschini A, Cominelli M, Medicina D, Cenzato M, Simoncini EL, Magrini SM, Buglione M, Grisanti S, Padovani A (2013) Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro-Oncol. doi: 10.1093/neuonc/nos338
9. Sun C, Wang Q, Zhou H, Yu S, Simard AR, Kang C, Li Y, Kong Y, An T, Wen Y, Shi F, Hao J (2013) Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo. Neurosci Bull 29(1):83-93. doi: 10.1007/s12264-012-1296-5
10. Wang L, Yuan J, Tu Y, Mao X, He S, Fu G, Zong J, Zhang Y (2013) Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma. Clin & Transl Oncol 15(2):139-145. doi: 10.1007/s12094-012-0900-5
11. Kesanakurti D, Chetty C, Dinh DH, Gujrati M, Rao JS (2013) Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma. Oncogene 32(3):327-340. doi: 10.1038/onc.2012.52
12. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, De Wever B, Calvo F, Mauviel A, Menashi S (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol 166(1):209-219. doi: 10.1016/S0002-9440(10)62245-6
13. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55(2):434-439
14. Yu XL, Hu T, Du JM, Ding JP, Yang XM, Zhang J, Yang B, Shen X, Zhang Z, Zhong WD, Wen N, Jiang H, Zhu P, Chen ZN (2008) Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem 283(26):18056-18065. doi: 10.1074/jbc.M802694200
15. Luo J, Teplyakov A, Obmolova G, Malia T, Wu SJ, Beil E, Baker A, Swencki-Underwood B, Zhao Y, Sprenkle J, Dixon K, Sweet R, Gilliland GL (2009) Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping. Proteins 77(4):1009-1014. doi: 10.1002/prot.22577
16. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56(7):359-367. doi: 10.1111/j.1440-1827.2006.01972.x
17. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L (2010) Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat 124(3):677-688. doi: 10.1007/s10549-010-0790-6
18. Li Y, Wu J, Song F, Tang J, Wang SJ, Yu XL, Chen ZN, Jiang JL (2012) Extracellular membrane-proximal domain of HAb18G/CD147 binds to metal ion-dependent adhesion site (MIDAS) motif of integrin beta1 to modulate malignant properties of hepatoma cells. J Biol Chem 287(7):4759-4772. doi: 10.1074/jbc.M111.277699
19. Zhu S, Li Y, Mi L, Zhang Y, Zhang L, Gong L, Han X, Yao L, Lan M, Chen Z, Zhang W (2011) Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci 56(12):3569-3576. doi: 10.1007/s10620-011- 1812-x
20. Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien A, Klauschen F (2012) High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol 43(9):1471-1481. doi: 10.1016/j.humpath.2011.10.023
21. Ueda K, Yamada K, Kiyokawa T, Iida Y, Nagata C, Hamada T, Saito M, Aoki K, Yanaihara N, Takakura S, Okamoto A, Ochiai K, Ohkawa K, Tanaka T (2012) Pilot study of CD147 protein expression in epithelial ovarian cancer using monoclonal antibody 12C3. J Obstet Gynaecol Res 38(9):1211-1219. doi: 10.1111/j.1447-0756. 2012.01853.x
22. Zhong X, Li M, Nie B, Wu F, Zhang L, Wang E, Han Y (2013) Overexpressions of RACK1 and CD147 associated with Poor prognosis in stage T1 pulmonary adenocarcinoma. Ann Surg Oncol 20(3):1044-1052. doi: 10.1245/s10434-012-2377-4
23. Bi XC, Liu JM, He HC, Ye YK, Han ZD, Dai QS, Liang YX, Cai C, Chen JH, Chen XB, Qin GQ, Zeng GH, Zhong WD (2012) Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin & Transl Oncol 14(3):190-196
24. Piao S, Zhao S, Guo F, Xue J, Yao G, Wei Z, Huang Q, Sun Y, Zhang B (2012) Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol 138(4):627-635. doi: 10.1007/s00432-011-1142-6
25. Zhong WD, Liang YX, Lin SX, Li L, He HC, Bi XC, Han ZD, Dai QS, Ye YK, Chen QB, Wang YS, Zeng GH, Zhu G, Zhang Z, Chen ZN, Wu CL (2012) Expression of CD147 is associated with prostate cancer progression. Int J Cancer J Int du Cancer 130(2):300-308. doi: 10.1002/ijc.25982
26. Afonso J, Longatto-Filho A, Baltazar F, Sousa N, Costa FE, Morais A, Amaro T, Lopes C, Santos LL (2011) CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol 37(9):811-817. doi: 10.1016/j.ejso.2011.06.006
27. Liu Y, Xin T, Jiang QY, Huang DY, Shen WX, Li L, Lv YJ, Jin YH, Song XW, Teng C (2013) CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol 30(1):366. doi: 10.1007/s12032-012-0366-x
28. Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, Koono M, Wakisaka S (2000) Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer J Int du Cancer 88(1):21-27
29. Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S (2013) Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. J Neurooncol. doi: 10.1007/s11060-013-1102-x
30. Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro-Oncol. doi: 10.1093/neuonc/not066
31. Liang Q, Xiong H, Gao G, Xiong K, Wang X, Zhao Z, Zhang H, Li Y (2005) Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther 4(7):759-762
32. Rosati A, Poliani PL, Todeschini A, Cominelli M, Medicina D, Cenzato M, Simoncini EL, Magrini SM, Buglione M, Grisanti S, Padovani A (2013) Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro-Oncol 15(5):618-625. doi: 10.1093/neuonc/nos338
33. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807-1812. doi: 10.1126/science.1164382
34. Sun J, Hemler ME (2001) Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61(5):2276-2281
35. Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y (2012) In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 7(8):e40716. doi: 10.1371/journal.pone.0040716
36. Huang JL, Wu SY, Xie XJ, Wang MX, Zhu S, Gu JR (2011) Inhibiting effects of leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. Eur J Pharmacol 670(1):304-310. doi: 10.1016/j.ejphar.2011.07.045
37. Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273(1):140-147. doi: 10.1016/j.canlet.2008.07.034
38. Kim JY, Kim H, Suk K, Lee WH (2010) Activation of CD147 with cyclophilin a induces the expression of IFITM1 through ERK and PI3K in THP-1 cells. Mediators Inflamm 2010:821940. doi: 10.1155/2010/821940
39. Xu HY, Qian AR, Shang P, Xu J, Kong LM, Bian HJ, Chen ZN (2007) siRNA targeted against HAb18G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Lett 247(2):336-344. doi: 10.1016/j.canlet.2006.05.017
40. Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93(2):199-204. doi: 10.1267/THRO05020199